Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.66 |
| ▸ | HTR7 | P34969 | 5/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | HTR6 | P50406 | 4/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966437 | 0.89 | HTR7 (0.69) | HTR2CHTR7HTR1AHTR2ADRD3 | |
| SCHEMBL302050 | 0.85 | HTR2C (0.53) | HTR2CHTR7HTR1AHTR2ADRD3 | |
| SCHEMBL301830 | 0.82 | HTR2C (0.61) | HTR2CHTR7HTR1AHTR2ADRD3 | |
| SCHEMBL3279825 | 0.81 | CYP11B1 (0.53) | HTR2CCYP11B1GRM2ALDH1A1LMNA | |
| SCHEMBL2188998 | 0.79 | ALDH1A1 (0.70) | CYP11B1GRM2ALDH1A1LMNAMEN1 | |
| SCHEMBL13064496 | 0.77 | LMNA (0.58) | CNR2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL13065208 | 0.76 | LMNA (0.59) | HTR2CGRM2LMNAKMT2A | |
| SCHEMBL303179 | 0.75 | HTR2C (0.54) | HTR2CHTR7HTR1AHTR2ADRD3 | |
| SCHEMBL303614 | 0.75 | HTR2C (0.58) | HTR2CHTR7HTR1AHTR2ADRD3 | |
| SCHEMBL303069 | 0.75 | HTR2C (0.55) | HTR2CHTR7HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | claimed |
| JP-2012500835-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | claimed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | HTR2C 3430/4885HTR7 2622/4885HTR1A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.